Krystal Biotech Inc Stock News

PITTSBURGH, July 20, 2020 -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1.

Invesco Ltd. reduced its stake in shares of Krystal Biotech Inc (NASDAQ:KRYS) by 57.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34

Rare Outreach Coalition has launched The Disorder Channel to showcase rare disease films and videos for free on Roku® and Amazon Fire TV.

Victory Capital Management Inc. lowered its position in Krystal Biotech Inc (NASDAQ:KRYS) by 24.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commissi

Voloridge Investment Management LLC reduced its stake in Krystal Biotech Inc (NASDAQ:KRYS) by 21.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund ow

Avrobio (NASDAQ:AVRO) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their ins

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma

There are already a bundle of designer bargains to be had at DEBRA stores, with locals donating items ranging from Michael Kors shoes to Diane von Furstenberg dresses.

The Hollywood hunk praised his friend Emma Fogarty who completed a gruelling walking challenge to raise much needed funds for DEBRA Ireland

The actor cycled 36km in support of Emma Fogarty, who crossed the finish line following a month-long assisted charity walk on Thursday.

Hollywood star Colin Farrell supported an Irish woman with a rare skin disease as she completed a gruelling charity challenge on Thursday.

Hollywood star Colin Farrell supported an Irish woman with a rare skin disease as she completed a gruelling charity challenge on Thursday.

JPMorgan Chase & Co. increased its position in shares of Krystal Biotech Inc (NASDAQ:KRYS) by 136.1% in the first quarter, Holdings Channel.com reports. The firm owned 46,645 shares of the company’s

Krystal Biotech Inc (NASDAQ:KRYS) has earned an average recommendation of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have

Krystal Biotech is using an engineered HSV-1 virus to topically treat serious dermatological conditions such as Recessive Dystrophic Epidermolysis Bullosa. Init